1-20 of 26
Mario Sznol
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B029: Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction

Xinxing Li, Tao Liu, Antonella Bacchiocchi, Mengxing Li, Wen Cheng, Tobias Wittkop, Fernando Mendez, Yingyu Wang, Paul Tang, George Yeung, Qianqian Yao, Marcus Bosenberg, Mario Sznol, Qin Yan, Malek Faham, Li Weng, Ruth Halaban, Hai Jin, Zhiqian Hu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): B029.
https://doi.org/10.1158/1557-3265.LIQBIOP24-B029
Published: 13 November 2024
View article titled, Abstract B029: Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
Journal Articles

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel-Ángel Berciano-Guerrero, Eva Muñoz Couselo, Delvys Rodríguez-Abreu, Valentina Boni, Lynn M. Schuchter, Maria Gonzalez-Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas O. Iannotti, Frank J. Hsu, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 74–81.
https://doi.org/10.1158/1078-0432.CCR-23-0475
Published: 05 January 2024
View article titled, A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Open the PDF for A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy in another window
Includes: Supplementary data
Journal Articles

Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma

Brooke Horowitch, Daniel Y. Lee, Min Ding, Sandra Martinez-Morilla, Thazin Nwe Aung, Feriel Ouerghi, Xueting Wang, Wei Wei, William Damsky, Mario Sznol, Harriet Kluger, David L. Rimm, Jeffrey J. Ishizuka
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2908–2918.
https://doi.org/10.1158/1078-0432.CCR-23-0215
Published: 01 August 2023
View article titled, Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Open the PDF for Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma in another window
Includes: Supplementary data
Journal Articles

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Tae Won Kim, Howard A. Burris, III, Maria J. de Miguel Luken, Michael J. Pishvaian, Yung-Jue Bang, Michael Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Jr, Andres Cervantes, Laura Q. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang-Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3452–3463.
https://doi.org/10.1158/1078-0432.CCR-21-4020
Published: 15 August 2022
View article titled, First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Open the PDF for First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

TIL in Melanoma—Similar Approaches, Different Results, Unanswered Questions

Mario Sznol
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5156–5157.
https://doi.org/10.1158/1078-0432.CCR-21-2450
Published: 01 October 2021
View article titled, TIL in Melanoma—Similar Approaches, Different Results, Unanswered Questions
Open the PDF for TIL in Melanoma—Similar Approaches, Different Results, Unanswered Questions in another window
Journal Articles

A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Sarah A. Weiss, Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia Jilaveanu, Amanda Ralabate, Barbara Johnson, Neta Shanwetter Levit, Gail Anderson, Daniel Zelterman, Wei Wei, Amit Mahajan, Ovid Trifan, Marcus Bosenberg, Susan M. Kaech, Curtis J. Perry, William Damsky, Scott Gettinger, Mario Sznol, Michael Hurwitz, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4757–4767.
https://doi.org/10.1158/1078-0432.CCR-21-0903
Published: 01 September 2021
View article titled, A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Open the PDF for A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1 in another window
Includes: Supplementary data
Journal Articles

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

Mark R. Middleton, Cheryl McAlpine, Victoria K. Woodcock, Pippa Corrie, Jeffrey R. Infante, Neil M. Steven, Thomas R. Jeffry Evans, Alan Anthoney, Alexander N. Shoushtari, Omid Hamid, Avinash Gupta, Antonella Vardeu, Emma Leach, Revashnee Naidoo, Sarah Stanhope, Sion Lewis, Jacob Hurst, Ita O’Kelly, Mario Sznol
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (22): 5869–5878.
https://doi.org/10.1158/1078-0432.CCR-20-1247
Published: 13 November 2020
View article titled, Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Open the PDF for Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study

Dmitriy Zamarin, Omid Hamid, Asha Nayak-Kapoor, Solmaz Sahebjam, Mario Sznol, Agron Collaku, Floyd E. Fox, Margaret A. Marshall, David S. Hong
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (17): 4531–4541.
https://doi.org/10.1158/1078-0432.CCR-20-0328
Published: 01 September 2020
View article titled, Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study
Open the PDF for Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Immunotherapy of Melanoma: Facts and Hopes

Sarah A. Weiss, Jedd D. Wolchok, Mario Sznol
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5191–5201.
https://doi.org/10.1158/1078-0432.CCR-18-1550
Published: 03 September 2019
View article titled, Immunotherapy of Melanoma: Facts and Hopes
Open the PDF for Immunotherapy of Melanoma: Facts and Hopes in another window
Journal Articles

Introducing a New Series: Immunotherapy Facts and Hopes

Ignacio Melero, Mario Sznol, Marlowe S. Tessmer, Theresa L. Whiteside, Jedd D. Wolchok
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1773–1774.
https://doi.org/10.1158/1078-0432.CCR-18-0408
Published: 12 April 2018
View article titled, Introducing a New Series: Immunotherapy Facts and Hopes
Open the PDF for Introducing a New Series: Immunotherapy Facts and Hopes in another window
Journal Articles

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Anthony W. Tolcher, Mario Sznol, Siwen Hu-Lieskovan, Kyriakos P. Papadopoulos, Amita Patnaik, Drew W. Rasco, Donna Di Gravio, Bo Huang, Dhiraj Gambhire, Ying Chen, Aron D. Thall, Nuzhat Pathan, Emmett V. Schmidt, Laura Q.M. Chow
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (18): 5349–5357.
https://doi.org/10.1158/1078-0432.CCR-17-1243
Published: 14 September 2017
View article titled, Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Open the PDF for Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors

Harriet M. Kluger, Christopher R. Zito, Gabriela Turcu, Marina K. Baine, Hongyi Zhang, Adebowale Adeniran, Mario Sznol, David L. Rimm, Yuval Kluger, Lieping Chen, Justine V. Cohen, Lucia B. Jilaveanu
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4270–4279.
https://doi.org/10.1158/1078-0432.CCR-16-3146
Published: 01 August 2017
View article titled, PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Open the PDF for PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Neil H. Segal, Theodore F. Logan, F. Stephen Hodi, David McDermott, Ignacio Melero, Omid Hamid, Henrik Schmidt, Caroline Robert, Vanna Chiarion-Sileni, Paolo A. Ascierto, Michele Maio, Walter J. Urba, Tara C. Gangadhar, Satyendra Suryawanshi, Jaclyn Neely, Maria Jure-Kunkel, Suba Krishnan, Holbrook Kohrt, Mario Sznol, Ronald Levy
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (8): 1929–1936.
https://doi.org/10.1158/1078-0432.CCR-16-1272
Published: 13 April 2017
View article titled, Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Open the PDF for Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody in another window
Includes: Supplementary data
Journal Articles

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Toni K. Choueiri, Mayer N. Fishman, Bernard Escudier, David F. McDermott, Charles G. Drake, Harriet Kluger, Walter M. Stadler, Jose Luis Perez-Gracia, Douglas G. McNeel, Brendan Curti, Michael R. Harrison, Elizabeth R. Plimack, Leonard Appleman, Lawrence Fong, Laurence Albiges, Lewis Cohen, Tina C. Young, Scott D. Chasalow, Petra Ross-Macdonald, Shivani Srivastava, Maria Jure-Kunkel, John F. Kurland, Jason S. Simon, Mario Sznol
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (22): 5461–5471.
https://doi.org/10.1158/1078-0432.CCR-15-2839
Published: 14 November 2016
View article titled, Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Open the PDF for Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

Harriet M. Kluger, Christopher R. Zito, Meaghan L. Barr, Marina K. Baine, Veronica L.S. Chiang, Mario Sznol, David L. Rimm, Lieping Chen, Lucia B. Jilaveanu
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (13): 3052–3060.
https://doi.org/10.1158/1078-0432.CCR-14-3073
Published: 30 June 2015
View article titled, Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites
Open the PDF for Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites in another window
Includes: Supplementary data
Journal Articles

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response

Mario Sznol, Lieping Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5542.
https://doi.org/10.1158/1078-0432.CCR-13-2234
Published: 01 October 2013
View article titled, Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response
Open the PDF for Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response in another window
Journal Articles

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

Mario Sznol, Lieping Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1021–1034.
https://doi.org/10.1158/1078-0432.CCR-12-2063
Published: 03 March 2013
View article titled, Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Open the PDF for Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer in another window
Journal Articles

Plasma Markers for Identifying Patients with Metastatic Melanoma

Harriet M. Kluger, Kathleen Hoyt, Antonella Bacchiocchi, Tina Mayer, Jonathan Kirsch, Yuval Kluger, Mario Sznol, Stephan Ariyan, Annette Molinaro, Ruth Halaban
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2417–2425.
https://doi.org/10.1158/1078-0432.CCR-10-2402
Published: 14 April 2011
View article titled, Plasma Markers for Identifying Patients with Metastatic Melanoma
Open the PDF for Plasma Markers for Identifying Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy

Jeffrey Weber, Michael Atkins, Patrick Hwu, Laszlo Radvanyi, Mario Sznol, Cassian Yee
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (7): 1664–1673.
https://doi.org/10.1158/1078-0432.CCR-10-2272
Published: 31 March 2011
View article titled, White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy
Open the PDF for White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy in another window
Journal Articles

C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas

Lucia B. Jilaveanu, Christopher R. Zito, Saadia A. Aziz, Patricia J. Conrad, John C. Schmitz, Mario Sznol, Robert L. Camp, David L. Rimm, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5704–5713.
https://doi.org/10.1158/1078-0432.CCR-09-0198
Published: 14 September 2009
View article titled, C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas
Open the PDF for C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas in another window
Includes: Supplementary data